InsermU999 retweeted
Montani David@Montanidavid
18 Apr 2025
Happy to share our latest publication from the fruitful collaboration between @InsermU999 & @Umr1180!
"Ca2+ Cycling Alteration in a Porcine Model of Right Ventricular Dysfunction" Circulation Heart Failure

@pulmotension @SPLF_SocPneumo @HTaPFrance
ahajournals.org/doi/10.1161/CI…
0
2
3
321
InsermU999 retweeted
Montani David@Montanidavid
25 Apr 2025
Happy to share our latest collaborative work: "Approach to Lung Transplantation in #PAH: A Delphi Consensus" just published online in Pulmonary Circulation
@SavaleL @pulmotension @SPLF_SocPneumo @InsermU999 @HTaPFrance

onlinelibrary.wiley.com/doi/10.1002/pu…
0
12
25
1,651
InsermU999 retweeted
Montani David@Montanidavid
1 May 2025
Thanks to the journal Chest #JournalCHEST for highlighting our article on the association between trastuzumab emtansine and pulmonary arterial hypertension #PAH
journal.chestnet.org/article/S0012-…

@SPLF_SocPneumo @HTaPFrance
@InsermU999 @pulmotension
CHEST
@accpchest
1 May 2025
INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (May 8): Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of #PAH?

Read the full research: hubs.la/Q03kydbt0
#MedEd #JournalCHEST
0
5
13
2,498
InsermU999 retweeted
Montani David@Montanidavid
2 May 2025
Proud to share our new publication in Respiratory Medicine and Research 'PAH-approved drugs in PH associated with COPD: a systematic literature review.'
Grateful to my co-authors !

@SPLF_SocPneumo
@pulmotension @SPLF_SocPneumo @InsermU999

sciencedirect.com/science/articl…
1
19
65
3,968
InsermU999 retweeted
Montani David@Montanidavid
7 May 2025
Phenotyping PH in COPD is a major challenge in respiratory medicine. Grateful for the great collaboration with the Strasbourg team. Our study is now out in ERJ Open Research

@pulmotension
@InsermU999
@SPLF_SocPneumo
@HTaPFrance

publications.ersnet.org/content/erjor/…
1
16
38
2,844
InsermU999 retweeted
Montani David@Montanidavid
8 May 2025
A key contribution on a major topic "Initial therapy in patients with #PAH and cardiovascular comorbidities" just published in @ERSpublications
Thanks to @AthenaisBoucly @SavaleL and the @pulmotension network

@SPLF_SocPneumo
publications.ersnet.org/content/erj/65…
0
16
22
2,264
InsermU999 retweeted
Olivier Sitbon@OSitbon
24 Oct 2024
#JRF-HTP @OSitbon @Montanidavid @AthenaisBoucly @jeanlucvachiery @madelcroix @OrphaLung @RespiFIL @pulmotension @Hopital_Bicetre @UnivParisSaclay
Société de Pneumologie de Langue Française (SPLF)@SPLF_SocPneumo
24 Oct 2024
Franc  succès des Journées du Réseau Français #Hypertension #Pulmonaire des 17 et 18 octobre 2024 au CHU de Bicêtre , centre national de référence
Avec 267 participants à l’auditorium du bâtiment recherche
0
3
13
621
InsermU999 retweeted
Montani David@Montanidavid
15 Feb 2025
Deeply concerning to receive #PAH study proposals from Akros Pharma, a pharmaceutical company emerging from Japan Tobacco Inc. The tobacco industry, responsible for 8 million deaths annually, has no place in medical research funding.
@SPLF_SocPneumo @EuroRespSoc @pulmotension
4
4
20
1,397
InsermU999 retweeted
Montani David@Montanidavid
8 Feb 2025
Happy to share our recent collaboration published in Rheumatology : "Anti-fibroblast and anti-endothelial cell autoantibodies in SLE- and MCTD-PAH"
@ThoreauBenjamin @pulmotension @InsermU999 @SPLF_SocPneumo
academic.oup.com/rheumatology/a…
2
4
12
1,529
InsermU999 retweeted
Montani David@Montanidavid
15 Jan 2025
Welcome to Grégoire Ruffenach to the Research Unit @InsermU999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies". Just arrived, and already full of projects and opportunities. Happy to have you on the team.
@pulmotension @HTaPFrance @SPLF_SocPneumo
2
1
10
517
InsermU999 retweeted
Sandeep Sahay, MD, MSc@SandeepSahayMD
14 Nov 2024
Professor Humbert sharing updates from the 7th WSPH
@DeBakeyCVedu @HMHCardioFellow @HMHpccm @EuropePHA @teamphhope @PHAssociation @ATS_PC @CHESTPulmCardio
One of the most important slides!!
0
2
12
461
InsermU999 retweeted
Sandeep Sahay, MD, MSc@SandeepSahayMD
16 Nov 2024
Amazing learning experience, discussions on PH, career mentoring, academic growth, food and fun over the last couple of days! @EuropePHA @ATS_PC @PHAssociation @HMHCardioFellow @HMethodistMD
Hyeon-Ju (HJ) Ali, MD@HJRyooAli
16 Nov 2024
Feeling inspired by Professor Humbert’s lectures this past week 🤩

✔️Weigh PAH & comorbidities in Rx
✔️Progress in genetic & pathobiology ➡️ sotatercept!
✔️Future research to improve upon current median survival of 7 yrs

Thank you @SandeepSahayMD for hosting & inviting me! #PH
0
2
14
1,195
InsermU999 retweeted
Montani David@Montanidavid
7 Nov 2024
The "DELPHI-2 Study" journey continue with our latest publication in Chest: "Role of Exercise Hemodynamics in the Prediction of #PAH in BMPR2 Mutation Carriers"
@pulmotension @SPLF_SocPneumo @InsermU999 @HTaPFrance @ChristianGerges @BogaardHarm
journal.chestnet.org/article/S0012-…
0
7
21
914
InsermU999 retweeted
Montani David@Montanidavid
17 Nov 2024
Happy to share this recent review "Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH" published in Blood Reviews
@pulmotension @LaurentBertole1 @InsermU999 @HTaPFrance @SPLF_SocPneumo
sciencedirect.com/science/articl…
1
9
28
1,359
InsermU999 retweeted
FSMR - RespiFIL 🫁@RespiFIL
17 Oct 2024
Replying to @RespiFIL
Élise Noël-Savina @CHUdeToulouse décrit les impacts des ces réévaluations pour le #diagnostic, les #cliniciens et aussi qui sont ces #patients.
0
3
6
402
InsermU999 retweeted
FSMR - RespiFIL 🫁@RespiFIL
17 Oct 2024
🔴 J1 [JRF-HTP] : session 2 - @Montanidavid intervient sur la réévaluation de la définition, la classification et le diagnostic de l’HTP par rapport aux guidelines @EuroRespSoc @ESC_Journals 2022 : déf. conservée, classe 3 modifiée avec des maladies.

🗞 erj.ersjournals.com/content/erj/ea…
1
3
11
462
InsermU999 retweeted
FSMR - RespiFIL 🫁@RespiFIL
18 Oct 2024
🔴 J2 [JRF-HTP] : session 5 - Marion Delcroix @UZLeuven présente les conclusions du #WSPH 2024 pour le traitement de l'#HTP thrombo-embolique chronique : #endartériectomie / l'#angioplastie pulmonaire et thérapie médicale ciblée HTP.
🗞 doi.org/10.1183/139930…

#CTEPH #PEA #BEA
1
3
7
327
InsermU999 retweeted
ATS Blue Journal@ATSBlueEditor
10 Sep 2024
The Blue Journal thanks Fabien Robert, PharmD, MSc, for his contribution to the September 1 issue

Disrupted BMP-9 Signaling Impairs Pulmonary Vascular Integrity in Hepatopulmonary Syndrome

atsjournals.org/doi/full/10.11…
0
5
10
1,042
InsermU999 retweeted
Société de Pneumologie de Langue Française (SPLF)@SPLF_SocPneumo
18 Oct 2024
#J2R : 200 participants , un superbe comité d'organisation et un joli programme sur 2 jours
#Recherche #Respiratoire #Pneumologie
1
6
15
872
InsermU999 retweeted
Société de Pneumologie de Langue Française (SPLF)@SPLF_SocPneumo
18 Oct 2024
Le congrès des J2R de la SPLF. Un énorme succès à Paris dans un lieu magnifique et de la recherche de haute volée.

Bravo à tous les laboratoires de recherche en pneumologie 🫁👏

👉 splf.fr/journees-de-re…
2
6
22
1,402
Load more